Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Abiomed, Inc.
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
December 21, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
First Patients in the World Treated with Impella RP Flex with SmartAssist
December 05, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
November 01, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
October 31, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
October 26, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
October 24, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
October 20, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath
October 17, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support
October 13, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification
October 13, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
September 20, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
September 19, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
September 17, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
September 16, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
September 13, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
August 04, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
July 14, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
June 14, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
May 31, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
April 28, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
April 08, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
First Patient in Japan Treated with Impella 5.5 with SmartAssist
April 06, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French
March 21, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 08, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year
February 03, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
January 14, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology
January 12, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study
January 10, 2022
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference
December 29, 2021
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Abiomed to Present at Upcoming Investor Conferences
November 18, 2021
From
Abiomed, Inc.
Via
Business Wire
Tickers
ABMD
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.